GRAIL, Inc. (GRAL) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Diagnostics & Research 行业. 公司总部位于 Menlo Park, CA, 美国. 现任CEO为 Robert Ragusa.
GRAL 拥有 IPO日期为 2024-06-12, 1,000 名全职员工, 在 NASDAQ Global Market, 市值为 $2.07B.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
